Calendar

Cloudflare’s reported Q2 2026 revenue growth and a $736.8M Q3 revenue consensus provide a credible business backdrop, but the stock fell sharply into the event: it lost roughly 15.5% from Oct. 26 to Oct. 30, including a high-volume down day. Required positive tape and estimate-upside signals are not supported.

ABNB has a small positive whisper-versus-consensus gap and recent company guidance describes strong revenue growth, but the guidance midpoint is slightly below the checked revenue consensus. The stock fell about 4.4% over five sessions, had no close above the 0.75 close-location threshold in the latest three sessions, and no confirmed 1.5x volume session; it does not qualify despite a supportive XLY tape.

EOG has upward EPS estimate revisions, a credible Q3 consensus, and a strong Oct. 30 close, but available checks did not establish positive revenue revisions or a recent >1.5x-volume accumulation day. The company has scheduled its Q3 results for Nov. 5 after close; its IR page separately lists a Nov. 6 results call.

Lumentum's September-quarter EPS estimate rose from $4.21 to $4.22 over the last month, and its prior company guidance midpoint for $1.25B revenue is in line with reported consensus; management cited accelerating AI-driven optical demand and the stock advanced sharply over the preceding five sessions. However, the late-week reversal and lack of a verified normal-volume comparator temper the setup, while valuation and execution risks remain material.

Simon has positive, though non-uniform, estimate momentum: checked consensus showed EPS up 1.74% and revenue up 3.69% over three months, and its latest reported quarter showed 96.0% occupancy, higher retailer sales, and raised full-year FFO guidance. The stock gained about 2.4% over five sessions and closed near the top of its Oct 30 range, but a normal-volume comparison was unavailable and its recent earnings history is uneven.

DVN has positive near-term estimate revisions, rising revenue expectations, four recent EPS beats per Zacks, and an official Nov. 5 reporting date; the stock also strengthened into the event. However, earnings-whisper EPS is below some consensus figures and the shares lagged the energy sector over the past month, while commodity exposure and transaction execution leave meaningful uncertainty.

Earnings Whispers reports a $1.48 whisper against $1.39 consensus, while the prior quarter had strong reported growth; however, no reliable pre-event revenue-revision, verified close-location, or volume-accumulation evidence was found for this screen, and the supplied latest close does not establish recent strength. The positive whisper alone is insufficient for qualification.

ED's reported date and consensus figures were available, and the recent close rose with XLU supportive; Con Edison had reaffirmed its 2026 adjusted EPS guidance. But no positive EPS revision, ESP, whisper, or revenue-upside signal was verified, and none of the last three checked sessions closed in the upper quarter of its range.

A pre-event Zacks article says the estimate-revision combination points toward a likely EPS beat, and recent annualized recovery expectations offer a possible cyclical catalyst. However, exact revision and current-quarter revenue consensus/upside evidence was not verifiable in the checked results, while Oct. 30 brought a high-volume 4.66% selloff and a weak close; it fails the required tape confirmation.

Live Nation has strong operating indicators ahead of the report: the latest available filing said 2026 event ticket sales were pacing 11% higher and deferred revenue reached a second-quarter record, while the stock recovered into Oct. 30 on a large-volume up day. But current-quarter revenue consensus estimates varied across checked providers and no positive EPS revision/ESP/whisper was verified; score remains below the required threshold.

The supplied Nov. 5 date conflicts with checked earnings sources: Earnings Whispers and MarketBeat indicate Nov. 4, while another estimate page shows Nov. 5 and cautions the date may move. Consensus estimates exist, but no positive revisions or required tape confirmation were established; reject on unconfirmed event date and incomplete signals.

MRNA has a modestly favorable EPS revision snapshot and a recent high-volume rebound, but the checked calendar sources describe Nov. 6 as estimated rather than company-confirmed, and no positive revenue revision or upside indicator was verified. The Oct. 22 melanoma-trial data leak coincided with a 17.57% drop and unusually high volume, leaving a volatile, event-driven tape.

Record Q2 fundraising and 20% fee-related-earnings growth, alongside a rising recent share price and several analyst target cuts, create a constructive but mixed backdrop. The checked sources support EPS and revenue consensus, but do not establish positive estimate revisions or an upside surprise signal; recent volume also falls short of a verified accumulation trigger.

Humana's primary IR estimate table showed near-flat Q3 EPS revisions and a credible consensus source provides EPS and revenue estimates, but the stock weakened into the event and underperformed the rising XLV. Medical-cost and Medicare policy uncertainty remain material, while recent tape did not confirm accumulation.

Vistra has a company-confirmed Nov. 6 report date and a strongly positive 30-day Q3 EPS revision, alongside long-term power-demand catalysts. However, shares declined about 5.4% from Oct. 26 through Oct. 30, recent closes were weak in their daily ranges, and the latest quarter missed consensus materially. Positive revisions alone do not offset the poor pre-event tape and limited recent execution evidence.

Tone is mixed: sales and digital growth contrast with lower fiscal Q4 profit and higher operating costs. The queue's October 13 earnings date conflicts with the confirmed October 6 company release. The packet supplies a $43.94 October 13 price anchor, but not a reliable pre-release close for calculating the post-print move. Post-print analyst revisions and consensus surprise data were not established; absence of those signals is not positive evidence. Social and options measures were not available.

The company release supports a positive operating update, while trusted coverage reported an initial 3.8% post-announcement share gain; whether that move holds is unconfirmed. [AZZ release](https://investor.azz.com/2026-10-13-AZZ-Inc-Reports-Fiscal-Year-2027-Second-Quarter-Results) [Initial reaction](https://www.investing.com/news/earnings/azz-jumps-over-3-on-record-q2-sales-raised-guidance-4947485) The earnings call and reliable post-print analyst revisions were unavailable at this T+1 checkpoint. Zero sentiment fields denote unavailable measurements, not neutral readings. The deterministic prior shifted from positive to neutral despite strong evidence quality, favoring monitoring rather than a stronger rating.

Earnings coverage is elevated, but the October 13 close was about 0.23% below the prior close after an early rally, tempering the positive surprise signal. [Price history](https://chartexchange.com/symbol/nyse-gs/historical/) One reported post-print EPS-estimate revision is available, but a verifiable price-target change and broader revision sample are not; the analyst headline claiming a raised target does not supply a target value. [Citizens revision report](https://www.investing.com/news/analyst-ratings/citizens-raises-goldman-sachs-price-target-on-stronger-earnings-outlook-93CH-4948437) Zero values in the quantitative sentiment fields denote unavailable measurements, not neutral readings.

The first post-print read is mixed: Q3 revenue and 2026 guidance rose, but MedTech missed management's expectations and JNJ closed October 13 at $248.61, down 5.73%. Coverage linked the selloff to the talc charge and MedTech weakness. No reliable post-print analyst target-change series is available, and conflicting consensus snapshots limit surprise precision; zero values in unobserved sentiment fields are placeholders, not measured readings. [historical close](https://chartexchange.com/symbol/nyse-jnj/historical/) [market coverage](https://uk.investing.com/news/stock-market-news/why-is-johnson--johnson-stock-tumbling-7-today-93CH-4908312)

The October 9 close of $82.17 was nearly flat versus October 8 despite the earnings miss and guidance cut; the October 13 anchor of $79.57 is about 3.2% lower. That later decline cannot be attributed solely to earnings because fuel-cost headlines also affected airlines. One verified post-print target cut is available, but a comprehensive estimate-revision set is not. Social, options, short-interest and employee metrics were not supplied; zero entries in the sentiment object mean unavailable, not neutral observations. [Historical closes](https://stockanalysis.com/stocks/dal/history/) [October 9 market coverage](https://www.kiplinger.com/investing/stocks/stocks-climb-a-wall-of-worry-ahead-of-earnings-stock-market-today) [UBS revision coverage](https://ca.investing.com/news/stock-market-news/ubs-cuts-delta-air-lines-stock-price-target-on-higher-costs-93CH-4876493)

News tone is mixed: company-reported Q3 growth and an earnings beat contrast with a 5.6% October 13 closing-price fall to $124.53. Zacks' $2.66 EPS and $23.66 billion revenue consensus imply a beat, but the available UBS target cut was pre-print, not a post-print revision. No reliable post-print estimate-change series, options skew, short-interest or social-coverage measure was supplied; zeroes in the sentiment object denote unavailable data, not neutral readings. [#SEC-8K-2026-10-13]